La Chemioterapia Adiuvante Nel Cancro Del Colon

Parkin D.M. , Pisani P. , Ferlay J. : Estimates of the worldwide incidence of eighteen major cancers in 1985. Int. J. Cancer, 55: 594–606, 1993.

Shulman K. , Schilsky R.L. : Adjuvant therapy of colon cancer. Semin. Oncol., 22: 600–610, 1995.

Verhaegen H. , De Cree J. , De Cock W. : Levamisole therapy in patients with colorectal cancer. In: Immunotherapy of human cancer, Terry W.D. , Rosenberg S.A. (Eds.), pp. 225–229, Elsevier, New York, 1982.

Laurie J.A. , Moertel C.G. , Fleming T.R. , Wieand H.S. , Leigh J.E. , Rubin J. , McCormack G.W. , Gerstner J.B. , Krook J.E. , Malliard J. : Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil: the NCCTG and the Mayo Clinic. J. Clin. Oncol, 7: 1447–1456, 1989.

Moertel C.G. , Fleming T.R. , MacDonald J.S. : Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. NEJM, 6: 352–358, 1990.

NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA, 264: 1444–1450, 1990.

IMPACT trial: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet, 345: 939–944, 1995.

O'Connell M. , Maillard J. , Kahn M.J. , MacDonald J. , Haller D.G. , Mayer R.J. , Wieand H.S. : Controlled trial of fluorouracil and low-dose leucovorin given for six months as post-operative adjuvant therapy for colon cancer. J. Clin. Oncol., 15: 246–250, 1997.

Wolmark N. , Rockette H. , Fisher B. , Wickerham D.L. , Redmond C. , Fisher E.R. , Jones J. , Marnounas E.P. , Ore L. , Petrelli N.J. : The benefit of leucovorin modulated 5-fluorouracil as post-operative adjuvant treatment for primary colon cancer: results from NSABP protocol C-03. J. Clin. Oncol., 11: 1879–1888, 1993.

Francini G. , Perioli R. , Lorenzini L. , Mancini S. , Armenio S. , Tanzini G. , Marsili S. , Aquino A. , Marzocca G. , Civitelli S. : Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology, 106: 899–906, 1994.

Wolmark N. , Rockette H. , Marnounas E.P. , Jones J. , Petrelli N. , Atkins J. , Dimitrov N. , Pugh R. , Wickerham D.L. , Wieand S. , Fisher B. : The relative efficacy of 5FU-leucovorin, 5FU-levamisole and 5FU-leucovorin-levamisole in patients with Dukes’ B and C carcinoma of the colon. First reports of NSABP C-04. Proc. Am. Soc. Clin. Oncol., 15: 205, 1996.

O'Connell M.J. , Laurie J.A. , Shepherd L. , Kahn M.J. , Pazdur R. , Fitzgibbons R.J. , Erlichman C. , Wieand H.S. : A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high risk colon cancer. A collaborative trial of the NCCTG and NCI-Canada Clinical trials. Proc. Am. Soc. Clin. Oncol., 15: 209, 1996.

Wolmark N. , Bryant J. , Hyams D.M. , Grem J. , Smith R. , Atkins J. , Dimitrov N. , Fisher B. , Oishi R. , Prager D. , Fehrenbacher L. , Romond E. , Colangelo L. : The relative efficacy of 5FU + leucovorin (FU-LV) and 5FU-LV + interferon alfa-2a (IFN) in patients with Dukes’ B and C carcinoma of the colon: first report of NSABP C-05. Proc. Am. Soc. Clin. Oncol., 17: 255, 1998.

Scheithauer W. , Kornek G. , Rosen H. , Sebesta C. , Marcell A. , Kwasny W. , Karall M. , Depisch D. : Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma. Eur. J. Cancer, 317: 1981–1986, 1995.

Piedbois P. , Buyse M. , Gray R. , Clarke M. , Wolmark N. , Metzger U. , Fielding L.P. , Gray B. , Taylor L. , Wereldsma J. , Rvan J. , Marsoni S. , Gruenagel H.H. : Portal vein infusion is an effective adjuvant treatment for patients with colorectal cancer. Proc. Am. Soc. Clin. Oncol., 14: 192, 1995.

Wolmark N. , Rockette H. , Wickerham D.L. , Fisher B. , Redmond C. , Fisher E.R. , Potvin M. , Davies R.J. , Jones J. , Robidoux A. : Adjuvant therapy of Dukes’ A, B and C adenocarcinoma of the colon cancer with portal-vein fluorouracil hepatic infusion: preliminary results of NSABP protocol C-02. J. Clin. Oncol., 8: 1466, 1990.

Zaniboni A. , Boffi L. , Arcangeli B. , Labianca R. , Nitti D. , Pancera D. , Scatizzi M. , Torri V. , Marsoni S. : The S.M.A.C. study: large-scale collaborative trial of adjuvant therapy in colon cancer. Feasibility analysis. Proc. Am. Soc. Clin. Oncol., 15: 202, 1996.

Riethmuller G. , Schneider-Gadicke E. , Schlimok G. : Randomised trial of monoclonal antibody for adjuvant treatment of resected Dukes’ C colorectal carcinoma. Lancet, 343: 1177–1183, 1994.

Vermorken J.B. , Claessen A.M. , VanTinteren H. , Gall H.E. , Ezinga R. , Meijer S. , Scheper R.J. , Meijer C.J. , Bloemena E. , Ransom J.H. , Hanna M.G. Jr. , Pinedo H.M. : Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet, 353: 345–350, 1999.

De Gramont A. , Bosset J.F. , Milan C. , Rougier P. , Bouche O. , Eitenne P.L. , Morvan F. , Louvet C. , Guillot T. , Francois E. , Bedenne L. : Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus versus bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup Study. J. Clin. Oncol., 15: 808–815, 1997.

De Gramont A. , Figer A. , Seymour M. , Homerin M. , le Bail N. , Cassidy J. , Boni C. , Cortes-Funes H. , Frever G. , Hendler D. , Luovet C. : A randomised trial of leucovorin and 5fluorouracil with or without oxaliplatin in advanced colorectal cancer (CRC). Proc. Am. Soc. Clin. Oncol., 17: 257, 1998.